Reply to COVID-19 in patients with hematological malignancies: Considering the role of tyrosine kinase inhibitors.

Cattaneo, Chiara; Cairoli, Roberto; Rossi, Giuseppe

Cattaneo, Chiara; Cairoli, Roberto; Rossi, Giuseppe.

Cattaneo C; Hematology, ASST-Spedali Civili, Brescia, Italy.
Cairoli R; Department of Hematology and Oncology, A.O. Ospedale Niguarda Cà Granda, Milan, Italy.
Rossi G; Hematology, ASST-Spedali Civili, Brescia, Italy.

Cancer ; 127(11): 1939, 2021 06 01.

Article in English | MEDLINE | ID: covidwho-1130473

Subject(s)

COVID-19; Hematologic Neoplasms; Agammaglobulinaemia Tyrosine Kinase; Hematologic Neoplasms/drug therapy; Humans; Protein Kinase Inhibitors/adverse effects; SARS-CoV-2

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Hematologic Neoplasms / COVID-19 Limits: Humans Language: English Journal: Cancer Year: 2021 Document Type: Article Affiliation country: Cncr.33431

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google